Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
On Tuesday, Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.50 billion. Eli Lilly expects fourth-quarter 2024 revenue of approximately $13.5 billion, representing a 45% year-over-year growth compared to the consensus of $13.97 billion. The company’s expected 2024 revenue is $400 million, or about 3%, below the guidance range issued during